These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 35032444)
1. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444 [TBL] [Abstract][Full Text] [Related]
2. Common teratogenic medication exposures-a population-based study of pregnancies in the United States. Wang Y; Smolinski NE; Thai TN; Sarayani A; Ewig C; Rasmussen SA; Winterstein AG Am J Obstet Gynecol MFM; 2024 Jan; 6(1):101245. PubMed ID: 38061552 [TBL] [Abstract][Full Text] [Related]
3. Prenatal Care Initiation and Exposure to Teratogenic Medications. Winterstein AG; Wang Y; Smolinski NE; Thai TN; Ewig C; Rasmussen SA JAMA Netw Open; 2024 Feb; 7(2):e2354298. PubMed ID: 38300617 [TBL] [Abstract][Full Text] [Related]
4. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance. MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328 [TBL] [Abstract][Full Text] [Related]
5. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009. van Gelder MM; Bos JH; Roeleveld N; de Jong-van den Berg LT Hum Reprod; 2014 Jan; 29(1):161-7. PubMed ID: 24105826 [TBL] [Abstract][Full Text] [Related]
6. The teratogenesis risk associated with antiseizure medication duotherapy in women with epilepsy. Vajda FJE; O'Brien TJ; Graham JE; Hitchcock AA; Perucca P; Lander CM; Eadie MJ Epilepsy Res; 2024 Feb; 200():107316. PubMed ID: 38340680 [TBL] [Abstract][Full Text] [Related]
7. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy. Bhakta J; Bainbridge J; Borgelt L Epilepsy Behav; 2015 Nov; 52(Pt A):212-7. PubMed ID: 26460786 [TBL] [Abstract][Full Text] [Related]
8. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222 [TBL] [Abstract][Full Text] [Related]
9. Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect. Diav-Citrin O; Shechtman S; Bar-Oz B; Cantrell D; Arnon J; Ornoy A CNS Drugs; 2008; 22(4):325-34. PubMed ID: 18336060 [TBL] [Abstract][Full Text] [Related]
10. The estimation of human teratogenic/fetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology. Czeizel AE Expert Opin Drug Saf; 2009 May; 8(3):283-303. PubMed ID: 19505262 [TBL] [Abstract][Full Text] [Related]
11. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors. Brent RL Pediatrics; 2004 Apr; 113(4 Suppl):957-68. PubMed ID: 15060188 [TBL] [Abstract][Full Text] [Related]
12. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy. Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate. Sarayani A; Albogami Y; Elkhider M; Hincapie-Castillo JM; Brumback BA; Winterstein AG BMJ Qual Saf; 2020 Aug; 29(8):636-644. PubMed ID: 31649165 [TBL] [Abstract][Full Text] [Related]
14. Human teratogens update 2011: can we ensure safety during pregnancy? Rasmussen SA Birth Defects Res A Clin Mol Teratol; 2012 Mar; 94(3):123-8. PubMed ID: 22328359 [TBL] [Abstract][Full Text] [Related]
15. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks. van Gelder MM; de Jong-van den Berg LT; Roeleveld N Hum Reprod; 2014 Jan; 29(1):168-83. PubMed ID: 24108217 [TBL] [Abstract][Full Text] [Related]
16. High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception. Panchal BD; Cash R; Moreno C; Vrontos E; Bourne C; Palmer S; Simpson A; Panchal AR J Am Board Fam Med; 2019; 32(4):474-480. PubMed ID: 31300567 [TBL] [Abstract][Full Text] [Related]
17. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy. Schaefer C; Meister R; Weber-Schoendorfer C Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462 [TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcome following exposure to permethrin and use of teratogen information. Kennedy D; Hurst V; Konradsdottir E; Einarson A Am J Perinatol; 2005 Feb; 22(2):87-90. PubMed ID: 15731987 [TBL] [Abstract][Full Text] [Related]
19. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example. Honein MA; Moore CA; Erickson JD Drug Saf; 2004; 27(14):1069-80. PubMed ID: 15554743 [TBL] [Abstract][Full Text] [Related]
20. Prescription of teratogenic medications in United States ambulatory practices. Schwarz EB; Maselli J; Norton M; Gonzales R Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]